257 related articles for article (PubMed ID: 32484595)
1. Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy.
Zhang Y; Schmidt-Wolf IGH
J Cell Physiol; 2020 Dec; 235(12):9291-9303. PubMed ID: 32484595
[TBL] [Abstract][Full Text] [Related]
2. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).
Schmeel LC; Schmeel FC; Coch C; Schmidt-Wolf IG
J Cancer Res Clin Oncol; 2015 May; 141(5):839-49. PubMed ID: 25381063
[TBL] [Abstract][Full Text] [Related]
3. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
4. Cytokine-induced killer cells/dendritic cells-cytokine induced killer cells immunotherapy combined with chemotherapy for treatment of colorectal cancer in China: a meta-analysis of 29 trials involving 2,610 patients.
Zhang L; Mu Y; Zhang A; Xie J; Chen S; Xu F; Wang W; Zhang Y; Ren S; Zhou C
Oncotarget; 2017 Jul; 8(28):45164-45177. PubMed ID: 28404886
[TBL] [Abstract][Full Text] [Related]
5. Cytokines for the induction of antitumor effectors: The paradigm of Cytokine-Induced Killer (CIK) cells.
Cappuzzello E; Sommaggio R; Zanovello P; Rosato A
Cytokine Growth Factor Rev; 2017 Aug; 36():99-105. PubMed ID: 28629761
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies.
Schmeel FC; Schmeel LC; Gast SM; Schmidt-Wolf IG
Int J Mol Sci; 2014 Aug; 15(8):14632-48. PubMed ID: 25196601
[TBL] [Abstract][Full Text] [Related]
8. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
9. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.
Mesiano G; Todorovic M; Gammaitoni L; Leuci V; Giraudo Diego L; Carnevale-Schianca F; Fagioli F; Piacibello W; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2012 Jun; 12(6):673-84. PubMed ID: 22500889
[TBL] [Abstract][Full Text] [Related]
10. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of chemotherapy with cytokine-induced killer cells in non-small cell lung cancer: A systematic review and meta-analysis of 32 randomized controlled trials.
Xiao Z; Wang CQ; Feng JH; Zhou MH; Wang YZ; Li NN; Sun YP; Liu SY; Yao XS; Li CW; Ma B; Ding J; Chen L
Cytotherapy; 2019 Feb; 21(2):125-147. PubMed ID: 30554868
[TBL] [Abstract][Full Text] [Related]
12. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells.
Jäkel CE; Schmidt-Wolf IG
Expert Opin Biol Ther; 2014 Jul; 14(7):905-16. PubMed ID: 24673175
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).
Hontscha C; Borck Y; Zhou H; Messmer D; Schmidt-Wolf IG
J Cancer Res Clin Oncol; 2011 Feb; 137(2):305-10. PubMed ID: 20407789
[TBL] [Abstract][Full Text] [Related]
14. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study.
Zhang J; Zhu L; Du H; He X; Yin Y; Gu Y; Liu L; Lu K; Guo R; Liu P; Shu Y
Biomed Pharmacother; 2015 Mar; 70():248-52. PubMed ID: 25776508
[TBL] [Abstract][Full Text] [Related]
15. Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application.
Meng Y; Yu Z; Wu Y; Du T; Chen S; Meng F; Su N; Ma Y; Li X; Sun S; Zhang G
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28301281
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer.
Wang M; Cao JX; Pan JH; Liu YS; Xu BL; Li D; Zhang XY; Li JL; Liu JL; Wang HB; Wang ZX
PLoS One; 2014; 9(11):e112662. PubMed ID: 25412106
[TBL] [Abstract][Full Text] [Related]
17. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
18. Clinical effect and safety of dendritic cell-cytokine-induced killer cell immunotherapy for pancreatic cancer: a systematic review and meta-analysis.
Liu YL; Yang LX; Zhang F; Tang BS; Zhao LT; Zhu JR; Jin QY; Wang RX; Li YM
Cytotherapy; 2019 Oct; 21(10):1064-1080. PubMed ID: 31462394
[TBL] [Abstract][Full Text] [Related]
19. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
20. Polysaccharides from Hedyotis diffusa enhance the antitumor activities of cytokine-induced killer cells.
Ma C; Wei Y; Liu Q; Xin Y; Cao G; Wang X; Yang P
Biomed Pharmacother; 2019 Sep; 117():109167. PubMed ID: 31387180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
